Literature DB >> 19501513

Combining selectivity and affinity predictions using an integrated Support Vector Machine (SVM) approach: An alternative tool to discriminate between the human adenosine A(2A) and A(3) receptor pyrazolo-triazolo-pyrimidine antagonists binding sites.

Lisa Michielan1, Chiara Bolcato, Stephanie Federico, Barbara Cacciari, Magdalena Bacilieri, Karl-Norbert Klotz, Sonja Kachler, Giorgia Pastorin, Riccardo Cardin, Alessandro Sperduti, Giampiero Spalluto, Stefano Moro.   

Abstract

G Protein-coupled receptors (GPCRs) selectivity is an important aspect of drug discovery process, and distinguishing between related receptor subtypes is often the key to therapeutic success. Nowadays, very few valuable computational tools are available for the prediction of receptor subtypes selectivity. In the present study, we present an alternative application of the Support Vector Machine (SVM) and Support Vector Regression (SVR) methodologies to simultaneously describe both A(2A)R versus A(3)R subtypes selectivity profile and the corresponding receptor binding affinities. We have implemented an integrated application of SVM-SVR approach, based on the use of our recently reported autocorrelated molecular descriptors encoding for the Molecular Electrostatic Potential (autoMEP), to simultaneously discriminate A(2A)R versus A(3)R antagonists and to predict their binding affinity to the corresponding receptor subtype of a large dataset of known pyrazolo-triazolo-pyrimidine analogs. To validate our approach, we have synthetized 51 new pyrazolo-triazolo-pyrimidine derivatives anticipating both A(2A)R/A(3)R subtypes selectivity and receptor binding affinity profiles.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19501513     DOI: 10.1016/j.bmc.2009.05.038

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  7 in total

Review 1.  Progress in structure based drug design for G protein-coupled receptors.

Authors:  Miles Congreve; Christopher J Langmead; Jonathan S Mason; Fiona H Marshall
Journal:  J Med Chem       Date:  2011-06-15       Impact factor: 7.446

2.  Predicting Subtype Selectivity for Adenosine Receptor Ligands with Three-Dimensional Biologically Relevant Spectrum (BRS-3D).

Authors:  Song-Bing He; Zheng-Kun Kuang; Dong Wang; De-Xin Kong
Journal:  Sci Rep       Date:  2016-11-04       Impact factor: 4.379

3.  The Influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl Moiety on the Adenosine Receptors Affinity Profile of Pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c]Pyrimidine Derivatives.

Authors:  Stephanie Federico; Sara Redenti; Mattia Sturlese; Antonella Ciancetta; Sonja Kachler; Karl-Norbert Klotz; Barbara Cacciari; Stefano Moro; Giampiero Spalluto
Journal:  PLoS One       Date:  2015-12-01       Impact factor: 3.240

4.  Chemoinformatics Profiling of the Chromone Nucleus as a MAO-B/A2AAR Dual Binding Scaffold.

Authors:  Maykel Cruz-Monteagudo; Fernanda Borges; M Natalia D S Cordeiro; Aliuska Morales Helguera; Eduardo Tejera; Cesar Paz-Y-Mino; Aminael Sanchez-Rodriguez; Yunier Perera-Sardina; Yunierkis Perez-Castillo
Journal:  Curr Neuropharmacol       Date:  2017-11-14       Impact factor: 7.363

5.  Logistic Regression of Ligands of Chemotaxis Receptors Offers Clues about Their Recognition by Bacteria.

Authors:  Takashi Sagawa; Ryota Mashiko; Yusuke Yokota; Yasushi Naruse; Masato Okada; Hiroaki Kojima
Journal:  Front Bioeng Biotechnol       Date:  2018-01-22

Review 6.  Machine and deep learning approaches for cancer drug repurposing.

Authors:  Naiem T Issa; Vasileios Stathias; Stephan Schürer; Sivanesan Dakshanamurthy
Journal:  Semin Cancer Biol       Date:  2020-01-03       Impact factor: 15.707

7.  Identification of a Novel Bcl-2 Inhibitor by Ligand-Based Screening and Investigation of Its Anti-cancer Effect on Human Breast Cancer Cells.

Authors:  Mei Wen; Zhen-Ke Deng; Shi-Long Jiang; Yi-di Guan; Hai-Zhou Wu; Xin-Luan Wang; Song-Shu Xiao; Yi Zhang; Jin-Ming Yang; Dong-Sheng Cao; Yan Cheng
Journal:  Front Pharmacol       Date:  2019-04-17       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.